Back to top
more

SESEN BIO, INC. (SESN)

(Delayed Data from NSDQ)

$1.30 USD

1.30
2,172,114

+0.07 (5.69%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SESEN BIO, INC. (SESN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

SESEN BIO, INC. (SESN) closed the most recent trading day at $0.56, moving +1.8% from the previous trading session.

Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.

SESEN BIO, INC. (SESN) Flat As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.

SESEN BIO, INC. (SESN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

SESEN BIO, INC. (SESN) closed the most recent trading day at $0.50, moving +0.38% from the previous trading session.

SESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

SESEN BIO, INC. (SESN) closed at $0.50 in the latest trading session, marking a -1.81% move from the prior day.

BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy

by Zacks Equity Research

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the BLA in 2020.

SESEN BIO, INC. (SESN) Stock Moves -0.43%: What You Should Know

by Zacks Equity Research

SESEN BIO, INC. (SESN) closed at $0.39 in the latest trading session, marking a -0.43% move from the prior day.

Wave Therapeutics (WVE) Up on Update From Huntington's Study

by Zacks Equity Research

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

by Zacks Equity Research

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

SESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

SESEN BIO, INC. (SESN) closed at $0.67 in the latest trading session, marking a -1.59% move from the prior day.

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

by Zacks Equity Research

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

by Zacks Equity Research

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID

by Zacks Equity Research

CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.

J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up

by Zacks Equity Research

J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.

Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer

by Zacks Equity Research

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

FDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill

by Zacks Equity Research

The FDA schedules a joint advisory committee meeting in November 2022 to review Perrigo's (PRGO) regulatory filing for the first-ever over-the-counter birth control pill.

Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study

by Zacks Equity Research

Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.

Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug

by Zacks Equity Research

The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.

Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study

by Zacks Equity Research

Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.

Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag

by Zacks Equity Research

Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.

GSK's NDA for Daprodustat to be Reviewed by an FDA Panel

by Zacks Equity Research

GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.

Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA

by Zacks Equity Research

The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.

AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer

Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why

by Zacks Equity Research

Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.